endo.digital
FDA-cleared diabetes management platform with AI-powered insulin optimization for Type 1 and Type 2 diabetes
Platform · Cloud SaaSCompany source
Company profile
About DreaMed Diabetes Ltd
DreaMed Diabetes Ltd is a pioneering health AI company that has been transforming diabetes management since 2014. The company developed endo.digital, the world's first FDA-cleared decision support software for both Type 1 and Type 2 diabetes. The platform uses a smart algorithm to analyze CGM, SMBG, and insulin delivery data to generate personalized insulin treatment recommendations that achieve close to 90% agreement with real-world endocrinologists from leading US health systems. endo.digital is a cloud-based SaaS platform that simplifies end-to-end diabetes management across all care settings including endocrinology, diabetes centers, primary care, internal medicine, remote patient monitoring, and population management. The platform features seamless EMR integration through partnership with Redox, eliminating manual documentation and reducing time per patient visit by up to 9 minutes. Clinical studies have demonstrated statistically significant improvements in A1C and Time in Range. Founded by leading endocrinologists, engineers, and data scientists, DreaMed has achieved five FDA clearances and holds six patents. The company serves healthcare provider organizations across the United States, with over 5,000 active patients on the platform as of 2024. DreaMed operates under stringent quality management systems adhering to ISO 27001, GDPR, HIPAA, and SOC 2 standards.
Company description DreaMed Diabetes Ltd official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at DreaMed Diabetes Ltd?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Type 1 Diabetes
- Type 2 Diabetes
Who it serves
- Diabetes Centers
- Endocrinology Clinics
- Health Systems
- Internal Medicine
- Primary Care
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Abbott FreeStyle Libre 3, Abbott FreeStyle Libre Pro, Ascencia Contour Next Link, Dexcom G4, Dexcom G6 Mobile, Dexcom G7, EMR systems via Redox, Insulet Omnipod DASH, Medtronic 630G, Medtronic 723, OneTouch Ultra 2, OneTouch Verio Flex, Tandem T:slim, Tandem T:Slim X2, Trividia True Metrix Pro.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Fifth FDA clearance (K232722) in 2024 enabling broader insulin treatment support. Surpassed 5,000 active patients on endo.digital in 2024. endo.digital released for public use in 2022.
Partnerships
Recorded partners
- Billings Clinic
- Boston Children's Hospital
- Redox (EMR integration partner)
- Yale New Haven Health System
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI TherapyNCT04043260 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Time in Range increase
Statistically significant clinical improvements
A1C improvement
Statistically significant clinical improvements
9 minutes reduction per patient visit
Time study at NEMG, Yale New Haven Health, Dec 2022 – Feb 2023
50% increase in CPT Code reimbursement eligible visits
Revenue study at Billings Clinic, 2022-2023
90% agreement with endocrinologists
Agreement with real-world endocrinologists from leading US health systems
NEMG (New England Medical Group), Yale New Haven Health
Reducing time per patient visit through streamlined diabetes management workflow
Up to 9 minutes reduction in time per patient visit
Billings Clinic
Improving financial outcomes and increasing CPT Code reimbursement eligibility
Over 50% increase in patient visits eligible for CPT Code reimbursement; demonstrated improved revenue capture
Boston Children's Hospital
Providing FDA-cleared decision support for diabetes management with algorithm-generated recommendations
Clinical team members trust algorithm recommendations, saving time and enabling lower licensure staff to work confidently without additional approval burden
Yale New Haven Health System
Simplifying CGM utilization and improving diabetes management workflow efficiency
Significantly higher growth in CGM adoption, billed encounters, and total charges compared to traditional care; 9 minutes reduction in time per patient visit
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from DreaMed Diabetes Ltd
Recent articles published on DreaMed Diabetes Ltd's official website.
Roche Accu-Chek Guide, Guide Me, or Aviva Connect Meter
Read on DreaMed Diabetes LtdYale New Haven Case Study
Read on DreaMed Diabetes LtdReliOn Premier BLU, Voice, or Classic meter
Read on DreaMed Diabetes LtdTrividia Health True Metrix Meter
Read on DreaMed Diabetes LtdOneTouch Verio IQ Meter
Read on DreaMed Diabetes Ltd07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.